GLAND PHARMA
Back to Balance Sheet
|
GLAND PHARMA Last 5 Year Total Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Liabilities | ₹12,449 Cr | ₹11,173 Cr | ₹10,611 Cr | ₹8,778 Cr | ₹7,834 Cr |
What is the latest Total Liabilities ratio of GLAND PHARMA ?
| Year | Total Liabilities |
|---|---|
| Mar2026 | ₹12,449 Cr |
| Mar2025 | ₹11,173 Cr |
| Mar2024 | ₹10,611 Cr |
| Mar2023 | ₹8,778 Cr |
| Mar2022 | ₹7,834 Cr |
How is Total Liabilities of GLAND PHARMA Trending?
| Years | Total Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹12,449 Cr | 11.42 | |
| Mar2025 | ₹11,173 Cr | 5.30 | |
| Mar2024 | ₹10,611 Cr | 20.89 | |
| Mar2023 | ₹8,778 Cr | 12.05 | |
| Mar2022 | ₹7,834 Cr | - | |
Compare Total Liabilities of peers of GLAND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLAND PHARMA | ₹49,071.8 Cr | 3.7% | 14.4% | 57.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹455,826.0 Cr | -1.6% | -2.5% | 21.4% | Stock Analytics | |
| DIVIS LABORATORIES | ₹247,019.0 Cr | 1.5% | 12.8% | 48.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹186,875.0 Cr | -0.9% | -0.8% | 35.3% | Stock Analytics | |
| CIPLA | ₹112,773.0 Cr | -1.6% | -5.2% | -11.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹95,570.9 Cr | -2.2% | -2.3% | -8.2% | Stock Analytics | |
GLAND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAND PHARMA | 3.7% |
14.4% |
57.3% |
| SENSEX | -1.1% |
-3.6% |
-5.3% |
You may also like the below Video Courses